A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy

Interleukin (IL)-7 is broadly active on T-cell populations, and modified versions have been clinically evaluated for a variety of therapeutic applications, including cancer, lymphopenia, and infectious diseases; and found to be relatively well-tolerated and biologically active. Here we describe nove...

Descripción completa

Detalles Bibliográficos
Autores principales: Dower, William J., Park, Angie Inkyung, Bakker, Alice V., Cwirla, Steven E., Pongtornpipat, Praechompoo, Williams, Blake M., Joshi, Prarthana, Baxter, Bryan A., Needels, Michael C., Barrett, Ronald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597491/
https://www.ncbi.nlm.nih.gov/pubmed/37874823
http://dx.doi.org/10.1371/journal.pone.0286834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597491/
https://www.ncbi.nlm.nih.gov/pubmed/37874823
http://dx.doi.org/10.1371/journal.pone.0286834

Ejemplares similares